For years, people taking Ozempic or other drugs in the same class for diabetes and weight loss have noticed the medicines don ...

Customers are to be offered discounted weight loss treatments through insurance giant Vitality in a UK first. The group, ...

Hims & Hers is under scrutiny for promoting compounded weight-loss drugs in a Super Bowl ad without clear FDA approval or ...

The next FDA Commissioner could solve two big problems with one powerful policy: encourage independent testing of both ...

The popular weight-loss drugs known as GLP-1 receptor agonists, which were originally meant to treat diabetes, surged in ...

Innogen, a Shanghai-based medical technology company, announced that its independently developed, human-derived, ...

Ozempic and Wegovy maker Novo Nordisk placed a print ad responding to the Super Bowl spot from competitor Hims & Hers.

Controversy surrounded Hims & Hers’ commercial, called ‘Sick of the System’, in the lead up to America’s biggest sporting ...

Eli Lilly has been a terrific stock to own for the past five years, thanks to its excellent clinical and regulatory progress. The company's breakthroughs are paying off. In each of the past six ...

Viking Therapeutics got the market's attention with robust phase 2 results for VK2735, a potential weight loss therapy.

An ad airing Super Bowl Sunday features “America’s deadliest epidemic,” obesity, and what can be done about it with the use of “affordable” compounded weight loss drugs.

Compounded semaglutide is legal, but it's not regulated in the same way as medications like Ozempic and Wegovy.